Related references
Note: Only part of the references are listed.Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate
J. Oldenburg et al.
HAEMOPHILIA (2014)
Updating Cost-Effectiveness - The Curious Resilience of the $50,000-per-QALY Threshold
Peter J. Neumann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries
D. Noone et al.
HAEMOPHILIA (2013)
Guidelines for the management of hemophilia
A. Srivastava et al.
HAEMOPHILIA (2013)
Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment
A. Farrugia et al.
HAEMOPHILIA (2013)
The principal results of the International Immune Tolerance Study: a randomized dose comparison
Charles R. M. Hay et al.
BLOOD (2012)
A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A
Kathelijn Fischer et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors
Cindy Leissinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cost of care of haemophilia with inhibitors
Matteo Nicola Dario Di Minno et al.
HAEMOPHILIA (2010)
How we treat a hemophilia A patient with a factor VIII inhibitor
Christine L. Kempton et al.
BLOOD (2009)
Health-related quality of life and productivity impact in haemophilia patients with inhibitors
T. M. Brown et al.
HAEMOPHILIA (2009)
Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project
R. Kulkarni et al.
HAEMOPHILIA (2009)
European Study on Orthopaedic Status of haemophilia patients with inhibitors
M. Morfini et al.
HAEMOPHILIA (2007)
Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors
B. A. Konkle et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Marilyn J. Manco-Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
International workshop on immune tolerance induction: consensus recommendations
D. M. Dimichele et al.
HAEMOPHILIA (2007)
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study
Jan Astermark et al.
BLOOD (2007)
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99
SC Darby et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group
A Gringeri et al.
BLOOD (2003)
Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors
C Knight et al.
HAEMOPHILIA (2003)
Control of bleeding in patients with haemophilia A with inhibitors: a systematic review
ML Jones et al.
HAEMOPHILIA (2003)
Share Paper
